▎WuXiEdited by Kant Content Team

Today, AstraZeneca announcedIts重磅PD-L1 inhibitor Imfinzi (durvalumab) and PARP inhibitor Lynparza (olaparib) have been approved in the European Union (EU) for the treatment of certain patients with primary advanced or recurrent endometrial cancer.Imfinzi in combination with chemotherapy as a first-line therapy, followed by Lynparza and Imfinzi, has been approved for the treatment of patients with proficient mismatch repair (pMMR). For patients with deficient mismatch repair (dMMR), Imfinzi in combination with chemotherapy followed by Imfinzi monotherapy has also been approved. According to the press release,This is the first approved combination of immunotherapy and PARP inhibitor for the treatment of endometrial cancer.

This approval is mainly based on the pre-specified exploratory subgroup analysis according to the patient's mismatch repair (MMR) status in the DUO-E phase 3 clinical trial, and the analysis results were published inJournal of Clinical OncologyJournal.The analysis shows,Compared with the control group, the Lynparza and Imfinzi regimen reduced the risk of disease progression or death by 43% (HR=0.57; 95% CI: 0.44-0.73) in patients with pMMR endometrial cancer.The median progression-free survival (PFS) was 15.0 months and 9.7 months in the two groups, respectively.In addition, compared with the control group,The Imfinzi regimen reduced the risk of disease progression or death by 58% (HR=0.42; 95% CI: 0.22-0.80) in dMMR patients.The median PFS in the Imfinzi group has not yet been reached, while the median PFS in the control group was 7.0 months.

The safety of the treatment regimens in the trial was manageable and well-tolerated, with safety profiles consistent with the known characteristics of each component drug.

Imfinzi is a monoclonal antibody that binds to the PD-L1 protein, blocking the interaction between PD-L1 and PD-1 and CD80 proteins., against tumor immune escape strategies, releasing the suppression of immune responses.Lynparza is a "first-in-class" PARP inhibitor and the first synthetic lethal targeted therapy drug., for targeting cells/tumors with homologous recombination repair (HRR) deficiencies (such as cells carrying BRCA1 and/or BRCA2 mutations).

▲To learn more about the application of cutting-edge technologies in the biopharmaceuticals industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] Lynparza and Imfinzi combination approved in the EU for patients with mismatch repair proficient advanced or recurrent endometrial cancer. Retrieved August 14, 2024 from https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-combination-approved-in-the-eu-for-patients-with-mismatch-repair-proficient-advanced-or-recurrent-endometrial-cancer.html

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views mentioned in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their WeChat Moments. Unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization, please reply "reprint" on the WeChat Official Account "WuXi AppTec" to obtain reprint guidelines.